Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.9 USD | -3.97% | -2.03% | -8.81% |
03-07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Sales 2024 * | 8.81M 704M | Sales 2025 * | 8.64M 690M | Capitalization | 23.54M 1.88B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.8B | Net income 2025 * | -39M -3.11B | EV / Sales 2024 * | 2.67 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.72 x |
P/E ratio 2024 * |
-1.03
x | P/E ratio 2025 * |
-1.45
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
Latest transcript on Lumos Pharma, Inc.
1 day | -3.97% | ||
1 week | -2.03% | ||
Current month | +3.20% | ||
1 month | +7.01% | ||
3 months | -3.01% | ||
Current year | -8.81% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 31/08/10 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 29/02/20 |
John McKew
PSD | President | 59 | 31/12/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 31/10/12 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 31/08/10 |
Kevin Lalande
BRD | Director/Board Member | 51 | 31/12/13 |
Date | Price | Change | Volume |
---|---|---|---|
10/05/24 | 2.9 | -3.97% | 32,880 |
09/05/24 | 3.02 | +0.66% | 31,555 |
08/05/24 | 3 | -0.66% | 12,524 |
07/05/24 | 3.02 | +0.67% | 26,542 |
06/05/24 | 3 | +1.35% | 43,425 |
Delayed Quote Nasdaq, May 10, 2024 at 09:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.81% | 23.54M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- LUMO Stock